건성안을 동반한 갑상샘안병증에서 0.05% 사이클로스포린 A 점안액 사용 후 눈물막과 안구표면의 변화
Effect of Topical 0.05% Cyclosporine A in Dry Eye Associated With Thyroid Ophthalmopathy
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 건성안을 동반한 갑상샘안병증 환자에서 0.1% 히알루론산나트륨과 0.05% 사이클로스포린 A 점안액 병합사용 후 눈물막과 안구 표면의 변화에 대하여 알아보고자 하였다. 대상과 방법: 0.1% 히알루론산나트륨만 사용한 18명 36안을 1군, 0.05% 사이클로스포린 A 점안액을 동시에 사용한 18명 36안을 2군으 로 나누어 사용 전과 사용 후 1, 3, 6개월에 각각 눈물막파괴시간, 기본눈물분비, 눈물청소율, 각막상피병증과 각막감각을 측정하고, 점안액 사용 전과 사용 후 3개월 째 인상세포 검사 및 눈물 내 CXCL (Chemokine (C-X-C motif) ligand) 11 농도를 측정하여 비교하였다. 결과: 1군에서는 눈물막파괴시간, 기본눈물분비, 눈물청소율, 각상피병증과 각막감각이 6개월째 호전되었으며(p＜0.05), 2군에서는 3 개월째 호전되었다(p＜0.05). 편평상피화생, 술잔세포밀도와 CXCL11 농도는 1군에서는 3개월째 차이가 없었으나, 2군에서는 3개월 째 호전되었다(p＜0.05). 결론: 건성안을 동반한 갑상샘안병증 환자에서 0.1% 히알루론산나트륨과 0.05% 사이클로스포린 A의 점안액의 병합 사용은 눈물막과 안구 표면 지표의 빠른 호전을 보이므로 효과적이라고 생각된다.
Abstract
Purpose: The present study was performed to evaluate the changes in tear film and ocular surface parameters after using sodium hyaluronate (SH) 0.1% alone or in combination with cyclosporine A (CsA) 0.05% in patients with thyroid- associated ophthalmopathy accompanied by dry eye. Methods: A total of 72 eyes from 36 patients were divided into two groups; 36 eyes of 18 patients were treated with 0.1% SH alone (group 1), and 36 eyes of 18 patients were treated with SH 0.1% and CsA 0.05% (group 2). Tear break-up time (BUT), basal tear secretion test (BST), tear clearance rate (TCR), fluorescein staining (FS) and corneal sensitivity test (CST) were evaluated at pre-treatment and one, three and six months post-treatment. Conjunctival impression cytology was performed and tear CXCL11 (Chemokine (C-X-C motif) ligand) levels were measured pre-treatment and three months post-treatment. Results: BUT, BST, TCR, KEP and CST were significantly improved at six months in group 1 (p < 0.05) and at three months in group 2 (p < 0.05). The degree of conjunctival squamous cell metaplasia, goblet cell density and tear CXCL11 levels were significantly changed at three months in group 2 (p < 0.05). However, there were no significant changes in group 1 after 3 months. Conclusions: Combined use of topical 0.1% SH and 0.05% CsA can result in early improvement in tear films and ocular surface parameters in patients with thyroid-associated ophthalmopathy accompanied by dry eye.
참고문헌 (36)
- Char DH, "Thyroid eye disease", Br J Ophthalmol, 80, pp.922~926 (1996)
- 임원일, "갑상선 안병증과 갑상선 기능상태의 연관성", 대한안과학회지, 43(3), pp.431~436 (2002), 대한안과학회
- Wiersinga WM, "Grave's ophthalmopathy: a rational approach to treatment", Trends Endocrinol Metab, 13, pp.280~287 (2002)
- Khurana A, "Tear film profile in Graves' ophthalmopathy", Acta Ophthalmol, 70, pp.346~349 (1992)
- Gilbard JP, "Ocular surface drying and tear film osmolarity in thyroid eye disease", Acta Ophthalmol, 61, pp.108~116 (1983)
- Pflugfelder SC, "The diagnosis and management of dry eye: a twenty-five-year review", Cornea, 19, pp.644~649 (2000)
- Nussenblatt RB, "Cyclosporine A: immunology, pharmacology and therapeutic uses", Surv Ophthalmol, 31, pp.159~169 (1986)
- Hemady R, "Immunosuppressive drugs in immune and inflammatory ocular disease", Surv Ophthalmol, 35, pp.369~395 (1991)
- Jabs DA, "The eye in bone marrow transplantation", Arch Ophthalmol, 107, pp.1343~1348 (1989)
- Bhan AK, "T-cell subsets and Langerhans cells in normal and diseased conjunctiva", Am J Ophthalmol, 94, pp.205~212 (1982)
- Gilbard JP, "Effect of punctal occlusion by Freeman silicone plug insertion on tear osmolarity in dry eye disorder", CLAO J, 15, pp.216~218 (1989)
- 이은하, "건성안에서 실리콘 누점마개 삽입술이 눈물 오스몰과 단백질 성분에 미치는 영향", 대한안과학회지, 42(11), pp.1509~1514 (2001), 대한안과학회
- Yen MT, "The effect of punctual occlusion on tear production, tear clearance and ocular surface sensation in normal subjects", Am J Ophthalmol, 131, pp.314~323 (2001)
- Pflugfelder SC, "Effects of sequential artificial tear and cyclosporine A emulsion therapy on conjunctival goblet cell density and transforming growth factor-β2 production", Cornea, 27, pp.64~69 (2008)
- Wilson SE, "Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine A treatment", Ophthalmology, 114, pp.76~79 (2007)
- Roberts CW, "Comparison of topical cyclosporine A, punctal occlusion, and a combination for the treatment of dry eye", Cornea, 26, pp.805~809 (2007)
- Mourits MP, "Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach", Br J Ophthalmol, 73, pp.639~644 (1989)
- Tsubota K, "Tear dynamics and dry eye", Retin Eye Res, 17, pp.565~596 (1998)
- Kaido M, "Punctal occlusion for Stevens-Johnson syndrome", Ophthalmology, 111, pp.895~900 (2004)
- Yoon KC, "Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease", Bone Marrow Transplant, 39, pp.231~235 (2007)
- Nelson JD, "Impression cytology", Cornea, 7, pp.71~81 (1988)
- Yoon KC, "Comparison of autologous serum and umbilical cord serum eye drops for dry eye syndrome", Am J Ophthalmol, 144, pp.86~92 (2007)
- Perry HD, "Dry eye diagnosis and management in 2004", Curr Opin Ophthalmol, 15, pp.299~304 (2004)
- O’Brien PD, "Dry eye: Diagnosis and current treatment strategies", Curr Allergy Asthma Rep, 4, pp.314~319 (2004)
- Small DS, "Blood concentrations of cyclosporin during long term treatment with cyclosporin ophthalmic emulsion in patients with moderate to severe dry eye disease", J Ocul Pharmacol Ther, 18, pp.411~418 (2002)
- Laibovitz RA, "Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca", Cornea, 12, pp.315~323 (1993)
- Raphael M, "Conjunctival biopsy in Sjögren's syndrome: correlations between histological and immunohistochemical features", Histopathology, 13, pp.191~202 (1988)
- Kunert KS, "Analysis of topical cyclosporine A treatment of patients with dry eye syndrome", Arch Ophthalmol, 118, pp.1489~1496 (2000)
- Turner K, "Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine A ophthalmic emulsion", Cornea, 19, pp.492~496 (2000)
- Stevenson D, "Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group", Ophthalmology, 107, pp.967~974 (2000)
- Jun Woong Moon, "Short Term Effects of Topical Cyclosporine and Viscoelastic on the Ocular Surfaces in Patients with Dry Eye", Korean Journal of Ophthalmology, 21(4), pp.189~194 (2007), 대한안과학회
- Altiparmak UE, "Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients", Eye, 16 (2009)
- 오한진, "건성안이 동반된 갑상샘안병증 환자에서 사이클로스포린 A 점안액 사용 후 눈물막과 안구표면의 변화", 대한안과학회지, 48(5), pp.630~636 (2007), 대한안과학회
- McInnis KA, "Human corneal epithelial cells synthesize ELR(-)alpha-chemokines in response to proinflammatory mediators", Ocul Immunol Inflamm, 15, pp.295~302 (2007)
- Cole KE, "Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3", J Exp Med, 187, pp.2009~2021 (1998)
- Yoon KC, "Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome", Invest Ophthalmol Vis Sci, 51, pp.643~650 (2010)